Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer
Loading...
Official URL
Full text at PDC
Publication date
2005
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
SPANDIDOS PUBL LTD
Citation
Morán A, Iniesta P, García-Aranda C, De Juan C, Díaz-López A, Sánchez- Pernaute A, Torres AJ, Díaz-Rubio E, Balibrea JL, Benito M. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. Oncol Rep. 2005 Jan;13(1):115-20. PMID: 15583811.
Abstract
The main aim of this study was to evaluate the clinical relevance of Gelatinases in colorectal cancer (CRC). Ninety-five CRCs and their paired normal tissues were investigated to detect total levels of MMP-9, MMP-2, and the tissue inhibitors TIMP-1 and TIMP-2. Also, pro-MMP and MMP activity, and potential associations with clinical parameters were estimated. MMP-9, MMP-2 and TIMP-1 levels were greater in CRCs than in normal tissues, differences being significant for MMP-9 and TIMP-1. However, TIMP-2 showed significantly lower levels in tumour samples. Moreover, significant differences in the state of activation between gelatinases were found. TIMP-1 low levels were significantly associated with poor clinical outcome of patients. According to these data, different roles have to be attributed to MMP-2 and MMP-9 in CRC progression. Moreover, TIMP-1 level evaluation emerges as the main prognostic factor in relation to Gelatinases A and B activity in CRC.